Join our daily newsletter At The Bell to receive exclusive market insights
- INOVIQ (IIQ) signs a contract services agreement with US-based contract diagnostics organisation ResearchDx to further develop and validate the company’s SubB2M-based tests in the US
- SubB2M-based tests are being developed for the monitoring and detection of cancer and its technology is based on an engineered protein that specifically detects the pan-cancer biomarker Neu5Gc found in multiple human cancers
- Under the agreement, ResearchDx will provide contract services including technology transfer, feasibility testing and assay development of the SubB2M-based tests, followed by analytical and clinical validation of the tests
- IIQ shares last traded at 86 cents on April 4
INOVIQ (IIQ) has entered into a contract services agreement with US-based contract diagnostics organisation ResearchDx to further develop and validate the company’s SubB2M-based tests in the US.
SubB2M-based tests are being developed for the monitoring and detection of cancer and its technology is based on an engineered protein that specifically detects the pan-cancer biomarker Neu5Gc found in multiple human cancers.
Under the agreement, ResearchDx will provide contract services including technology transfer, feasibility testing and assay development of the SubB2M-based tests, followed by analytical and clinical validation of the tests.
ResearchDx will initially undertake technology transfer, feasibility testing and assay development of the SubB2M-based tests incorporating the SubB2M/CA15.3 test for monitoring breast cancer, the SubB2M/CA125 test for monitoring ovarian cancer and the SubB2M-SPR test for detection of Neu5Gc concentrations.
INOVIQ will pay the agreed costs for the ResearchDx work and related sample, reagent and consumable expenditures.
“As a specialist contract diagnostic organisation with a US-based CAP/CLIA-certified laboratory, ResearchDx is an ideal partner to help progress the development and
commercialisation of our SubB2M-based tests in the US,” INOVIQ CEO Dr Leearne Hinch said.
“This agreement is important as it delivers two milestones in one with ResearchDx providing accredited CRO services and being a potential clinical laboratory partner for SubB2M-based lab developed tests in the US.”
IIQ shares last traded at 86 cents on April 4.
